Bleomycin-induced pulmonary fibrosis is independent of eosinophils.
Eosinophils have been shown to increase in tissues during many fibrotic conditions and consequently have been suggested to contribute to the development of fibrosis. This study tested the hypothesis that eosinophils are essential in the development of lung fibrosis in mice in response to bleomycin (BLM). Anti-IL-5 antibody was administered intraperitoneally into mice 2 h prior to endotracheal BLM inoculation and thereafter, every other day. Lung eosinophilia was evaluated by measurement of eosinophil peroxidase activity and confirmed by eosinophil counts in histologic sections. Lung fibrosis was evaluated by hydroxyproline content and confirmed by collagen staining in histological sections. Results demonstrated that BLM induced pronounced lung eosinophilia, which was maximal 7 days after BLM treatment and remained elevated through day 14, in C57B1/6 SCID mice and CBA/J mice. In contrast, eosinophilia was a minor component in the lungs of wildtype C57B1/6 mice after BLM treatment, although lung fibrosis developed similarly in all three strains of mice. Treatment with anti-IL-5 completely abrogated eosinophilia but failed to block pulmonary fibrosis induced by BLM in all mouse strains, including C57B1/6 SCID, wildtype C57B1/6 mice, and CBA/J mice. Analysis of cytokine mRNA by RNase-protection assay in C57B1/6 SCID mice indicated that BLM treatment caused enhanced expression of the cytokines, TNF-alpha, and IL-6 at days 3, 7, and 14 post-BLM inoculation, regardless of whether eosinophils were depleted by anti-IL-5. Finally, the importance of eosinophils in lung fibrosis was examined in IL-5 gene knockout mice (IL-5tm1Kopf). BLM treatment induced significant lung fibrosis in IL-5 knockout mice in the absence of eosinophilia. These findings indicate that eosinophils are not an absolute requirement for BLM-induced pulmonary fibrosis in the mouse.
Hao
H
H
Department of Microbiology and Immunology, the Graduate Center for Toxicology, University of Kentucky, College of Medicine, Lexington 40536-0084, USA.
Cohen
D A
DA
Jennings
C D
CD
Bryson
J S
JS
Kaplan
A M
AM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D001761:Bleomycin / Q000633:toxicity*; D003094:Collagen / Q000032:analysis; D047209:Eosinophil Peroxidase; D004804:Eosinophils / Q000502:physiology*; D005786:Gene Expression Regulation / Q000187:drug effects; D006909:Hydroxyproline / Q000032:analysis; D015848:Interleukin-5 / Q000037:antagonists & inhibitors / Q000172:deficiency / Q000235:genetics / Q000276:immunology; D015850:Interleukin-6 / Q000096:biosynthesis / Q000235:genetics; D008168:Lung / Q000737:chemistry / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D018345:Mice, Knockout; D016513:Mice, SCID; D010544:Peroxidases / Q000032:analysis; D011657:Pulmonary Eosinophilia / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D013047:Specific Pathogen-Free Organisms; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000235:genetics
D000911:Antibodies, Monoclonal; D015848:Interleukin-5; D015850:Interleukin-6; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D001761:Bleomycin; D003094:Collagen; D047209:Eosinophil Peroxidase; D010544:Peroxidases; D006909:Hydroxyproline